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Purpose: Bacillus Calmette-Guérin (BCG) vaccine has widely been used to immu-
nize against tuberculosis, but its protective efficacy is variable in adult pulmonary 
tuberculosis, while it is not efficiently protective against progressive infection of 
virulent Mycobacterium tuberculosis strains. In this study, the protective effects of 
plasmid DNA vaccine constructs encoding IL-12 or IL-18 with the BCG vaccine 
were evaluated against progressive infection of M. tuberculosis, using mouse aero-
sol challenge model. Materials and Methods: Plasmid DNA vaccine constructs 
encoding IL-12 or IL-18 were constructed and mice were immunized with the 
BCG vaccine or with IL-12 DNA or IL-18 DNA vaccine constructs together with 
the BCG vaccine. Results: The BCG vaccine induced high level of interferon gam-
ma (IFN-γ) but co-immunization of IL-12 or IL-18 DNA vaccine constructs with 
the BCG vaccine induced significantly higher level of IFN-γ than a single BCG 
vaccine. The BCG vaccine was highly protective at early stage of M. tuberculosis 
infection, but its protective efficacy was reduced at later stage of infection. The co-
immunization of IL-12 DNA vaccine constructs with the BCG vaccine was slightly 
more protective at early stage of infection and was significantly more protective at 
later stage infection than a single BCG vaccine. Conclusion: Co-immunization of 
IL-12 DNA vaccine with the BCG vaccine induced more protective immunity and 
was more effective for protection against progressive infection of M. tuberculosis. 
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INTRODUCTION
Tuberculosis (TB) has a long history with human beings, and it is still considered 
to be a major infectious disease in the world. One third of the world’s population is 
infected with Mycobacterium tuberculosis, a cause of TB, which causes high mor-
bidity and mortality.1,2 Current situation has been worsened by co-infection with hu-
man immunodeficiency virus and by emergence of multi-drug resistant or extensive-
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bovis BCG (Pasteur strain 1173P2) used in this study were 
prepared as previously described.21 Briefly, M. tuberculosis 
and M. bovis BCG were grown for about 10 days at 37°C 
as a surface pellicle on Sauton medium enriched with 0.4% 
sodium glutamate and 3.0% glycerine. The surface pellicles 
were collected and disrupted with 6 mm glass beads by gen-
tle vortexing. After clumps were settled down, the upper 
suspension was collected and aliquots were stored at -70°C 
until use. After thawing, viable organisms were then count-
ed by plating serial dilutions on the Middlebrook 7H11 agar 
(Difco, Detroit, MI, USA). For inoculation into mice, bac-
terial suspensions were sonicated briefly in a sonic bath and 
diluted with phosphate-buffered saline (PBS) to reach de-
sired bacilli numbers. 
Culture filtrate protein antigens (CFP) were produced 
from the culture of M. bovis BCG as previously described.21 
Briefly, M. bovis BCG was grown in Sauton medium on an 
orbital shaker for 7 days. The supernatants were sterile fil-
tered and concentrated via ultrafiltration over an Amicon 
ultrafiltration stirred cell (Amicon, Danvers, MA, USA) fit-
ted with a PM10 membrane (Millipore, Bedford, MA, 
USA). Samples were further concentrated to a final volume 
of about 5 mL by centrifugation in a Savant speed-Vac (Sa-
vant Instruments, Holbrook, NY, USA). These preparations 
were aliquoted in 1 mL samples and stored at -20°C. Resid-
ual endotoxin levels were <50 IU/mg as determined by a 
Limulus amebocyte lysate assay (Cambrex, East Ruther-
ford, NJ, USA).
Plasmid DNA construction 
The vector pGX10 expressing IL-12 or IL-18 was prepared 
as described previously.16,22 Briefly, pGX10, plasmid DNA 
vector, was generated by replacing the ampicillin resistance 
cassette of pTV2 with the kanamycin resistance cassette. 
pGX10 is composed of a cytomegalovirus (CMV) immedi-
ate-early gene promoter, tripartite leader (TPL) sequences, 
simian virus 40 (SV40) late polyA tail, and an SV40 en-
hancer, linked in tandem. For generation of pGX10-IL-12, 
murine IL-12p35 (p35), the internal ribosomal entry site 
(IRES) of encephalomyocarditis virus, and murine IL-
12p40 (p40) were also linked in a tandem, unidirectionally 
arranged and inserted into pGX10 vector, resulting in 
pGX10-p35/IRES/p40 (pGX10-IL-12) (Fig. 1). For genera-
tion of pGX10-IL-18, murine IL-18 cDNA was provided 
kindly from Bank for Cytokine Research at Chonbuk Uni-
versity. IL-18 cDNA was inserted into pGX10 vector (Fig. 
1). pGX10, pGX10-IL-12, and pGX10-IL-18 plasmid DNA 
ly-drug resistant M. tuberculosis strains. M. bovis bacillus 
Calmette-Guérin (BCG) has been utilized worldwide as an 
effective anti-TB vaccine,3 however, its protective efficacy is 
variable, ranging from 0 to 80%, against pulmonary TB.4 
Furthermore, the BCG vaccine-induced immune responses 
decrease gradually three months after vaccination in hu-
mans.5 In animal model, the BCG vaccine is protective 
against M. tuberculosis challenge, but the protective efficacy 
of the BCG vaccine decreases 6-12 months post-immuniza-
tion.6-8 The BCG vaccine is protective at early stage of infec-
tion against several M. tuberculosis strains, but can not effi-
ciently protect the progression of M. tuberculosis infection, 
especially against highly virulent M. tuberculosis strains.9,10
Cytokines play a key role in cell-mediated immune re-
sponses because they are able to modulate the immune re-
sponse and enhance the protective immune response. Inter-
feron gamma (IFN-γ) is a typical T helper 1 (Th1) cytokine 
that is secreted mainly by cluster of differentiation 4 (CD4) 
and CD8 T-cells,11 and has been known as a key cytokine 
for protective immunity against TB.12 IL-12 and IL-18 are 
representative cytokines produced by activated macro-
phages, dendritic cells and natural killer (NK) cells, that 
promote the production of IFN-γ of T-cells.13-15 IL-12 or IL-
18 has shown good adjuvant effects on the BCG vaccine, 
protein subunit vaccine, and plasmid DNA vaccine.14,16- 20
In this study, we investigated whether co-immunization 
of plasmid DNA vaccine constructs, encoding IL-12 or IL-
18, with the BCG vaccine could enhance the protective im-
munity of the BCG vaccine and efficiently protect the pro-
gression of M. tuburculosis infection, using an aerosol 
challenge mouse model.
MATERIALS AND METHODS
Mice 
Specific pathogen-free female C57BL/6 mice at 5-6 weeks 
of age were purchased from Japan SLC, Inc. (Shijuoka, Ja-
pan), maintained under barrier conditions in a biohazard 
animal room at Yonsei University Medical Research Cen-
ter, and fed a sterile commercial mouse diet and water. All 
animal experiments were done according to the regulation 
of Institutional Animal Care and Use Committee, Yonsei 
University Health System.
Bacteria and antigens 
Mycobacterium tuberculosis H37Rv (ATCC 27294) and M. 
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lymphocytes in a 200 µL volume of RPMI 1640 supple-
mented with 5×10-5 M 2-mercaptoethanol, 1% penicillin-
streptomycin, 1 mM glutamine, and 10% (vol/vol) fetal calf 
serum. The splenocytes were stimulated in triplicate culture 
with CFP at final concentration of 10 µg/mL or with medi-
um only. The splenocytes were incubated at 37°C in the 
presence of 5 % CO2 for 6 days, the supernatants were tak-
en, and IFN-γ present in culture supernatants was quanti-
fied using a mouse IFN-γ OptEIATM Set (Pharmingen, San 
Diego, CA, USA) according to the manufacturer’s instruc-
tions. In brief, enzyme immunoassay (EIA) plates (Costar, 
Cambridge, MA, USA) were coated overnight with 2 µg/mL 
monoclonal anti-mouse IFN-γ in polycarbonate buffer 
(pH9.2) at 4°C. Free binding sites were blocked with PBS 
containing 0.05% Tween 20 (PBST) and 5% normal goat 
serum, followed by washing with PBST. Culture superna-
tants of day 6 for IFN-γ were added into wells in triplicate, 
and the plate was then incubated overnight at 4°C. The re-
combinant mouse IFN-γ was used as a standard. The wells 
were then washed four times with PBST, and IFN-γ was de-
tected with a biotin-labeled rat anti-mouse IFN-γ monoclo-
nal antibody and phosphate-conjugated streptoavidin. After 
six times washing with PBST, the enzyme reaction was de-
veloped with O-phenylenediamine (Sigma-Aldrich Chemi-
cal Co., St. Louis, MO, USA) and hydrogen peroxide. Op-
tical density was measured by an automatic EIA reader 
(Molecular Devices Co., Sunnyvale, CA, USA) after stop-
ping the reaction by adding 2.5 N H2SO4, and the quantity 
of IFN-γ was calculated by comparing with the results ob-
tained with its standard.
M. tuberculosis infection and bacterial counts
Mice were challenged by aerosol exposure with M. tuber-
culosis H37Rv using an inhalation device (Glas-Col, Terre 
for immunization were prepared by cesium chloride density 
gradient centrifugation which was performed at 50,000 rpm 
for 15 h at 20°C using a Beckman LE80 ultracentrifuge.22
 
Immunization of mice 
Mice were immunized with experimental vaccines as previ-
ously described.22 Mice were given subcutaneously a single 
dose (2×105 CFU/mouse) of the BCG vaccine in a volume of 
200 µL on the back. For DNA vaccination, mice were inject-
ed twice at 3-weeks intervals intramuscularly into the quadri-
ceps muscle with 50 µg of pGX10, pGX10-IL-12 or pGX10-
IL-18 DNA vaccine constructs in a volume of 200 µL. For 
the co-immunization of plasmid DNA vaccine constructs and 
the BCG vaccine, mice were injected together subcutaneous-
ly with the BCG vaccine and simultaneously with the plas-
mid DNA intramuscularly at the first immunization, and then 
were injected intramuscularly with plasmid DNA on the third 
week after the first immunization. For negative controls, 
mice were injected subcutaneously with 200 µL of sterile py-
rogen-free saline or, intramuscularly with 50 µg of pGX10, 
pGX10-IL-12, and pGX10-IL-18 DNA vaccine constructs.
Mouse lymphocyte culture and IFN-γ assays 
Mycobacterial antigen-specific immune responses were 
measured as previously described.21 Mice were sacrificed 
on the fourth week after last immunization, and spleens 
were removed from three mice in each experimental group. 
Splenocytes were obtained by preparing single-cell suspen-
sion from spleens by dispersion of the tissue with sterilized 
slide glasses. Erythrocytes were lysed with a solution con-
taining 155 mM ammonium chloride and 10 mM potassi-
um bicarbonate buffer, and cells were thoroughly washed. 
Isolated cells were cultured in 96-well cell culture plates 
(Nunc, Roskilde, Denmark), each well containing 2×105 
Fig. 1. Construction of plasmid DNA encoding IL-12 and IL-18. Plasmid DNA vector, pGX10, is composed of a CMV promotor, TPL, SV40 late 
polyA tail, and an SV40 enhancer. pGX10-IL-12 was generated by insertion of murine IL-12p35, the internal ribosomal entry site (IRES) of 
encephalomyocarditis virus, and murine IL-12p40. pGX10-IL-18 was generated by insertion of murine IL-18. SV40, simian virus 40; pCMV, 
CMV promoter; TPL, tripartite leader sequences; CMV, cytomegalovirus.
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tistical software (version 2.6.2). A p-value of less than 0.05 
was considered statistically significant.
RESULTS
 
IFN-γ production by co-immunization of plasmid DNA 
vaccine constructs encoding IL-12 or IL-18 with the 
BCG vaccine 
Production of IFN-γ, a key cytokine of the protective im-
mune response against TB, was examined to investigate 
whether DNA vaccines encoding IL-12 or IL-18 cytokine 
were able to augment the protective immune response of 
the BCG vaccine. Thus, splenocytes from three mice from 
each group were isolated after four weeks of last immuni-
zation and were stimulated with CFP or media for 6 days, 
and IFN-γ levels in the supernatants were measured. The 
level of CFP-reactive IFN-γ in the BCG vaccinated mice 
was approximately 2,000 pg/mL (Fig. 2). The levels of 
CFP-reactive IFN-γ in the groups co-immunized with the 
BCG vaccine and IL-12 or IL-18 DNA vaccine were ap-
proximately 3,000 pg/mL and 4,600 pg/mL, respectively 
(Fig. 2), which were significantly higher than that in the 
BCG vaccine (p<0.01 and p<0.001, IL-12 and IL-18 DNA 
vaccine constructs, respectively). The levels of CFP-reac-
tive IFN-γ in the pGX10 vector, IL-12 and IL-18 DNA vac-
cine constructs-immunized mice were below 200 pg/mL as 
naïve mice (data not shown).
Protective effects of plasmid DNA vaccine constructs 
encoding IL-12 or IL-18 on the BCG vaccine against 
progression of M. tuberculosis infection 
To evaluate the effect of the plasmid DNA vaccine con-
structs encoding cytokines on the protective efficacy of the 
BCG vaccine, ten immunized mice per group were chal-
lenged by aerosol exposure with a virulent strain of M. tuber-
culosis, and the protective efficacy of the vaccine candidates 
was measured by comparing the bacterial burdens in the or-
gans of vaccinated mice to those of naïve mice (Fig. 3).
The protective efficacy was measured at 30 days post-in-
fection, which is the point when M. tuberculosis bacilli un-
dergoes exponential growth and reaches peak in the lungs. 
The bacterial CFUs in naïve mice at 30 days post-infection 
were 6.37±0.13 log and 5.41±0.04 log in the lungs and 
spleens, respectively. There were significant bacterial re-
ductions in the BCG vaccinated mice [1.1 log (p<0.001) in 
the lungs and 0.67 log (p<0.01) in the spleens, respectively] 
Haute, IN, USA) which was calibrated to deliver approxi-
mately 200 bacteria into the lungs as previously de-
scribed.10,22 Mice were challenged on the fourth week after 
the last immunization, and five mice per group were sacri-
ficed at 30 and 90 days post-challenge and bacterial counts 
were determined from tissue homogenates of the lung and 
spleen. The numbers of viable bacteria in the lung and 
spleen were determined by plating with serial dilution of 
whole organ homogenates on Middlebrook 7H11 agar (Dif-
co, Detroit, MI, USA). Colonies were counted after 3-4 
weeks incubation at 37°C. The resulting values are based 
on the experimental group of five mice and are presented as 
means of log10CFU±standard deviation per group.
Histopathology of lung 
Lungs were excised from all animals and stored in 10% 
formalin, and then embedded and stained with haematoxy-
lin and eosin (H&E) for pathological analysis. The level of 
inflammation in the lungs was evaluated as previously de-
scribed.10 In brief, H&E stained lung sections were photo-
graphed using a microscope (Olympus BX51, Olympus 
Co., Tokyo, Japan), and the level of inflammation present in 
the images was analyzed using the ImageJ program (Na-
tional Institutes of Health, MD, USA). The resulting values 
are presented as the mean percent of inflamed area from 
lung sections of five mice per group.
Statistical analysis 
Analyses were performed by the ANOVA test using R sta-
Fig. 2. IFN-γ production from splenocytes by experimental vaccines. Spleno-
cytes were prepared from three mice per group 30 days after the last vac-
cination and then stimulated with CFP antigens in vitro. The level of IFN-γ 
after 6 days of incubation was analyzed. The experiments were repeated 
three times with similar results, and the data from one representative exper-
iment are shown. The results are expressed as the mean amounts of IFN-γ 
(pg/mL) of three mice (±SD) per group. p-value less than 0.05 was consid-
ered to be significant and was represented as follows: IFN-γ, interferon 
gamma; CFP, culture filtrate protein antigens; BCG, Bacille-Calmette-Guerin. 
*p<0.05, **p<0.001.
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of CFUs in the spleens compared to the BCG vaccinated 
mice, but it was not significant.
Pulmonary pathology after M. tuberculosis infection 
The level of lung inflammation was assessed to evaluate 
the effectiveness of IL-12 or IL-18 DNA vaccine constructs 
on the BCG vaccine. Thus, mice were sacrificed at 30 and 
90 days post-infection and five H&E stained lung sections 
per group were analyzed using the ImageJ software. Repre-
sentative lung sections and the lung inflammation values 
are shown in Fig. 4 and Table 1. In the lungs of naïve mice, 
considerable and consolidated inflammation was seen, and 
the mean inflammation values were 38% and 43% at 30 
and 90 days post-infection, respectively. In the BCG vacci-
nated mice, less inflammation was observed, and the mean 
inflammation values were significantly lower compared to 
naïve group (p<0.001 and p<0.01, at 30 and 90 days post-
infection, respectively). In the vector DNA, IL-12 DNA, or 
IL-18 DNA vaccine constructs-immunized mice, the levels 
of inflammation in the lungs were similar to that of naïve 
mice group. In the co-immunized mice of IL-12 DNA or 
IL-18 DNA vaccine constructs with the BCG vaccine, lung 
inflammations were not improved at 30 days post-infection, 
but interestingly, the less lung inflammation was observed 
in the co-immunized mice of IL-12 DNA and the BCG vac-
cine at 90 weeks post-infection compared to the BCG vac-
cinated mice (p<0.05).
DISCUSSION
  
The BCG vaccine induces cellular immune responses, and 
CD4 T-cell is major protective machinery against TB, which 
compared to naïve control group. There were no significant 
bacterial reductions in the IL-12 or IL-18 DNA vaccine-im-
munized mice (data not shown). There was a significant bac-
terial reduction not only in the lungs but also in the spleens of 
mice co-immunized with IL-12 DNA vaccine and the BCG 
vaccine (0.3 log, p<0.05; in the spleen). However, there was 
no significant bacterial reduction in the mice co-immunized 
with IL-18 DNA vaccine, and the BCG vaccine.
To examine whether IL-12 or IL-18 DNA vaccine con-
struct helps the BCG vaccine prevent the progression of M. 
tuberculosis infection, mice were sacrificed and bacterial 
CFUs were measured at 90 days post-infection (Fig. 3). 
The CFUs in the naïve mice were 6.13 log and 5.62 log in 
the lungs and spleens, respectively, at 90 days post-infec-
tion. The CFUs in the BCG vaccine-immunized mice were 
increased at 90 days post-infection (5.76 log and 5.00 log in 
the lungs and spleens, respectively) compared to CFUs at 
30 days post-infection. The protective efficacy of the BCG 
vaccine was reduced to 0.37 log (p<0.05) in the lungs at 90 
days post-infection. There was no significant protective ef-
ficacy in the IL-12 or IL-18 DNA vaccine-immunized mice 
at 90 days post-infection (data not shown).
Although CFUs in the mice co-immunized of with IL-12 
DNA vaccine and the BCG vaccine was increased at 90 
days post-infection compared to at 30 days post-infection, 
this vaccine induced high significant protective efficacy in 
the lungs and spleens at 90 days post-infection (p<0.001 
both lungs and spleens). Interestingly, however, there were 
significant bacterial reductions in the lung (0.30, p<0.05) 
and spleen (0.47 log, p<0.01) compared to the BCG vacci-
nated mice. The co-immunization of IL-18 DNA vaccine 
with the BCG vaccine induced significant protective effica-
cy at 90 days post-infection and there was a little reduction 
Fig. 3. Protective efficacy of experimental vaccines. Ten mice per group were immunized with the BCG vaccine singly, and co-immunized with the BCG vac-
cine and IL-12 DNA or IL-18 DNA vaccine. Immunized mice were infected by aerosol exposure with virulent M. tuberculosis H37Rv. The number of CFUs was 
measured in the lungs (A) and spleens (B) of five mice per group at 30 and 90 days post-challenge. The level of protection of experimental vaccines was cal-
culated as CFUs in the naïve minus CFUs in the vaccinated mice. Data are represented as log10 CFU±SD, where n=5 and data is representative of two experi-
ments. The ANOVA test was used to determine the significance of differences between experimental groups. p-value less than 0.05 was considered as signif-
icant and represented as follows; *p<0.05, **p<0.01, and ***p<0.001. BCG, bacillus Calmette-Guérin; CFU, colony forming unit; ANOVA, analysis of variance.
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could enhance IFN-γ production compared to the BCG 
vaccine alone. These results are consistent with the previ-
ous reports: Palendira, et al.’s reported that IL-12 DNA vac-
cine constructs induced plasmid DNA encoding mycobac-
terial antigen to produce the Th1 immune response,18,19 and 
Triccas, et al.20 showed that IL-18 DNA vaccine constructs 
augmented IFN-γ production of the DNA vaccine encoding 
TB antigen. These results suggest that IL-12 or IL-18 DNA 
vaccine constructs have a synergistic effect on the protec-
tive immune response by the BCG vaccine.
In the present study, the BCG vaccine induced highly 
secretes cytokines such as IFN-γ and TNF-α resulting in the 
activation of macrophages to kill infected M. tuberculosis. 
Antigen-presenting cells such as macrophages or dendritic 
cells, reversely, can enhance the functions of T cell immune 
machinery. Th1 cytokines such as IL-12 or IL-18, secreted 
by macrophages or dendritic cells, can act as an adjuvant to 
moderate immune responses of T-cells.14,16,19
In the present study, IL-12 or IL-18 cytokines in the form 
of plasmid DNA were evaluated as an adjuvant of the BCG 
vaccine against progressive TB. Co-immunization of IL-12 
or IL-18 DNA vaccine constructs with the BCG vaccine 
Table 1. Lung Inflammation Values in Naïve and Vaccinated Mice at 30 and 90 days Post-Infection with M. 
tuberculosis H37Rv Strain
Group
Mean inflammation value† (% of the lung section inflamed)
30 days post-infection 90 days post-infection
Naïve   38.2±4.3    43.1±6.4
GX10   40.2±2.4    45.3±7.1
BCG 20.7±5.1**  31.9±3.8*
BCG+GX10 21.3±3.8**  29.5±4.7*
BCG+IL-12 18.5±3.6**     22.3±5.1**‡ 
BCG+IL-18 23.6±2.7**  30.5±3.1*
Significantly reduced lung inflammation in the vaccinated mice relative to naïve control is indicated as follows: *p<0.01, **p<0.001.
†Lung inflammation values are presented as the mean percentage of the area of inflammation from lung lections of five mice per group 
(±standard deviation).  
‡Lung inflammation value of coimmunized mice of IL-12 DNA vaccine with BCG vaccine is significantly lower than that of BCG-vaccinat-
ed mice at 12 weeks post-infection (p<0.05).
Fig. 4. Histopathology of lungs after aerosol infection with virulent M. tuberculosis. The right middle lobe of the lungs of mice was removed 
after 90 days post-challenge and lung sections were stained with H&E (×20). The representative histopathology of lungs of naïve mice (A), 
the BCG vaccine-immunized mice (B), co-immunized mice of the BCG vaccine and IL-12 DNA vaccine (C), and IL-18 DNA vaccine (D).
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